Heartflow Inc. filed an S-1 with the SEC on July 17, joining a wave of 15 med-tech companies with IPOs in 2025, underscoring ongoing investor interest in healthcare innovation technologies. The US False Claims Act continues to influence life sciences compliance, with states deepening their enforcement efforts, raising legal and operational stakes for companies. These developments spotlight the dual pressures of market expansion and regulatory scrutiny in med-tech and biotech sectors.